bioAffinity Technologies

Home
United States
San Antonio, TX
bioAffinity Technologies

Addressing the need for noninvasive diagnosis of early-stage cancer and targeted cancer treatment. www.cypathlung.com

Our flagship product, CyPath® Lung, is a noninvasive early lung cancer diagnostic.

07/29/2026

Risk stratification is one way clinicians determine the most appropriate path forward for patients with indeterminate pulmonary nodules.

CyPath Lung provides additional diagnostic information that helps clinicians assess malignancy risk and provides assurance to anxious patients that they are undergoing an invasive biopsy for the right reasons.

Learn more: https://www.cypathlung.com/

07/27/2026

Every pulmonary nodule tells only part of the story. When alone doesn't tell the whole story, physicians need more information.

bioAffinity Technologies (Nasdaq: BIAF) has published a new white paper examining how CyPath® Lung fits into pulmonary nodule evaluation across pulmonology, primary care and oncology. The challenge is determining which patients need invasive procedures and which can be safely monitored.

Drawing on three years of commercial experience, the publication presents a practical clinical framework for using CyPath® Lung's flow cytometry+AI platform to detect lung cancer and surveil survivors.

Read the white paper and news release: https://bit.ly/4pE16BW

07/24/2026

At 85 years old and a history of lung disease, avoiding an unnecessary invasive medical procedure can be a good thing.

CyPath Lung provided this physician with additional diagnostic insight about his patient’s pulmonary nodule that helped avoid a risky biopsy. Follow-up monitoring showed resolution of the nodule without further intervention.

CyPath Lung’s flow cytometry+AI technology supports individualized patient management and more informed decision-making.

Learn more: https://www.cypathlung.com/

07/22/2026

Why do some asthma and COPD patients respond to treatment while others don't?

Personalized medicine starts with understanding the underlying biology of each patient's disease. That's why we're excited to collaborate with Pictor to advance bioAffinity's next-generation lung inflammation diagnostics designed to help match patients with the right therapy.

The collaboration combines bioAffinity Technologies' expertise in flow cytometry with Pictor's targeted proteomic platform to analyze immune cell populations and cytokine profiles from sputum. Together, these technologies provide a more complete picture of lung inflammation—information that could help clinicians identify the type and severity of inflammation in patients with asthma and COPD and make more informed treatment decisions.

Read more about the collaboration: https://bit.ly/4fgOzB3

07/22/2026

How do you determine which patients with an indeterminate lung nodule may be appropriate candidates for biopsy?

CyPath Lung provides additional diagnostic information by assessing the lung microenvironment with flow cytometry+AI to help clinicians assess malignancy risk and make more informed clinical decisions about next steps.

Learn more: https://www.cypathlung.com/

07/21/2026

📢 Happening today!

Join bioAffinity Technologies, Philips and 4DMedical for an educational webinar focused on lung health screening and early detection for veterans.

Hear from clinical experts as they discuss lung cancer risk among veterans, the evolving role of imaging, emerging noninvasive diagnostic approaches and considerations for comprehensive lung health programs.

⏰ Today at 6 p.m. ET / 5 p.m. CT

Register here: https://bit.ly/4vY2VvD

07/17/2026

When evaluating pulmonary nodules, sometimes the best next step isn't an invasive procedure.

CyPath Lung provides additional diagnostic insight to help clinicians assess malignancy risk and support patient management decisions. In this physician's experience, the CyPath Lung result supported a decision to monitor instead of moving to biopsy for a patient whose follow-up CT scan showed the nodule was stable.
Learn more: https://www.cypathlung.com/

07/16/2026

Screening is the first step. A recent JAMA study reinforces the importance of getting more high-risk patients to participate in recommended lung cancer screening, estimating that broader screening among eligible individuals could save >62,000 lives over five years.

After screening, CyPath Lung is a noninvasive way to help determine if there is malignancy in the lung and risk-stratify patients at risk for lung disease. Innovative tools like CyPath Lung complement imaging by supporting clinical decision-making and easing patient anxiety.

Read the Medscape commentary: https://wb.md/4h3c0yQ

Read the study: https://bit.ly/3QNfZ8e

07/15/2026

Pulmonary nodules can present uncertainty for both clinicians and patients.

CyPath® Lung provides real-time actionable results that help clinicians assess malignancy risk and determine the most appropriate next steps in patient care. Early insight can support decisions about whether “watchful waiting” or intervention is appropriate while helping patients feel more informed throughout the process.

Learn more: https://www.cypathlung.com/

07/14/2026

One week from today, the National Association of Veterans' Research and Education Foundations will host a webinar exploring emerging approaches to veteran lung health.

Clinical experts from Philips, 4DMedical and bioAffinity Technologies will discuss lung cancer risk among veterans, advances in imaging, emerging noninvasive diagnostic approaches and opportunities to improve access to screening and follow-up care.

📅 July 21, 2026
⏰ 6 p.m. ET / 5 p.m. CT

Reserve your spot: https://bit.ly/4vY2VvD

Address

3300 Nacogdoches Road Ste 216
San Antonio, TX
78217

Telephone

+12106985334

Website

https://bioaffinitytech.com/

Alerts

Be the first to know and let us send you an email when bioAffinity Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.